FDA Draft Guidance on AI in Drug Development Explained
This whitepaper analyzes the FDA's draft guidance on AI in drug development, detailing its implications for industry practices and regulatory compliance.
- Publisher
- IntuitionLabs
- Published
- Length
- 24 pages
- File
- 548 KB PDF
Quick answer
FDA Draft Guidance on AI in Drug Development Explained is a 24-page whitepaper from IntuitionLabs covering US pharma intelligence. This whitepaper analyzes the FDA's draft guidance on AI in drug development, detailing its implications for industry practices and regulatory compliance.
Why this matters
This whitepaper analyzes the FDA's draft guidance on AI in drug development, detailing its implications for industry practices and regulatory compliance.
Executive summary
- This whitepaper analyzes the FDA's draft guidance on AI in drug development, detailing its implications for industry practices and regulatory compliance.
Market Impact
| Regulatory | high |
|---|---|
| Commercial | high |
| Competitive | medium |
| Investment | high |
Who should read this
- Regulatory affairs teams
Ask about this report
AI-assisted answers grounded in NovaPharmaNews intelligence
Answers use retrieved site intelligence plus AI synthesis. Verify critical decisions with primary sources.
Download the full 24-page PDF
Free · 548 KB · Instant access after email
This report provides an in-depth analysis of the FDA's draft guidance on the use of artificial intelligence (AI) in drug development, issued in January 2025. Key findings include:
Frequently asked questions
What whitepapers does NovaPharmaNews publish?
Our research library curates FDA, EMA, and industry publisher PDFs — regulatory guidance, clinical analyses, manufacturing reports, and market intelligence. Each report includes an AI-summarized landing page with key takeaways and a gated PDF download.
How do I download a whitepaper?
Open any report page, scroll to the download form, and enter your work email. You receive instant PDF access and can opt in to weekly pharma intelligence updates. Downloads are free for healthcare professionals.
How do whitepapers connect to news and pipeline data?
Report pages link to related intelligence — company profiles, drug INN pages, clinical trials, pipeline programs, and topic hubs. Use the intelligence spokes on each page to explore the entity graph behind the research.
Ready to read the full report?
Join 12,000+ pharma leaders getting deep industry analysis delivered weekly.
Related topic hubs
Editorial coverage and intelligence directories for this report's beat.
Explore the intelligence platform
Related intelligence
🔒 IFPMA IDAP whitepaper: end-to-end access pathway for innovative medicines and vaccines
IDAP is a holistic framework spanning four linked phases: Research and Development; regulatory processes and product registration; listing, …
🔒 IFPMA whitepaper: How assessment reports enable regulatory reliance in pharma
Regulatory reliance helps NRAs avoid duplicative reviews and allocate resources more efficiently by leveraging prior scientific evaluations …
🔒 Integrated delivery networks in Middle East healthcare: what PwC says about the next phase of care
Scale creates value only when healthcare assets are connected through shared systems, referral flows and coordinated management disciplines